



Clinical Multigene Panel Sequencing Identifies Distinct Mutational Association Patterns in Metastatic Colorectal Cancer

OPEN ACCESS

Edited by:

Ye Wang,
Qingdao University Medical
College, China

Reviewed by:

Valentina Silvestri,
Sapienza University of Rome, Italy
Alexandre Harle,
Institut de Cancérologie de
Lorraine, France
Hongxing Liu,
Lu Daopei Hospital, China

*Correspondence:

Giuseppe Giannini
giuseppe.giannini@uniroma1.it

†These authors have contributed
equally to this work

Specialty section:

This article was submitted to
Cancer Genetics,
a section of the journal
Frontiers in Oncology

Received: 02 October 2019

Accepted: 27 March 2020

Published: 07 May 2020

Citation:

Belardinelli F, Capalbo C, Malapelle U,
Pisapia P, Raimondo D, Milanetti E,
Yasaman M, Liccardi C, Paci P,
Sibillio P, Pepe F, Bonfiglio C, Mezi S,
Magri V, Coppa A, Nicolussi A,
Gradilone A, Petroni M, Di Giulio S,
Fabretti F, Infante P, Coni S,
Canettieri G, Troncone G and
Giannini G (2020) Clinical Multigene
Panel Sequencing Identifies Distinct
Mutational Association Patterns in
Metastatic Colorectal Cancer.
Front. Oncol. 10:560.
doi: 10.3389/fonc.2020.00560

Francesca Belardinelli^{1†}, Carlo Capalbo^{1†}, Umberto Malapelle², Pasquale Pisapia², Domenico Raimondo¹, Edoardo Milanetti³, Mahdavian Yasaman¹, Carlotta Liccardi¹, Paola Paci⁴, Pasquale Sibillio⁴, Francesco Pepe², Caterina Bonfiglio⁵, Silvia Mezi⁶, Valentina Magri⁷, Anna Coppa⁸, Arianna Nicolussi⁸, Angela Gradilone¹, Marialaura Petroni⁹, Stefano Di Giulio¹, Francesca Fabretti¹, Paola Infante⁹, Sonia Coni¹, Gianluca Canettieri^{1,10}, Giancarlo Troncone² and Giuseppe Giannini^{1,10*}

¹ Department of Molecular Medicine, University La Sapienza, Rome, Italy, ² Department of Public Health, University Federico II, Naples, Italy, ³ Department of Physics, University La Sapienza, Rome, Italy, ⁴ Institute for System Analysis and Computer Science "Antonio Ruberti", National Research Council, Rome, Italy, ⁵ National Institute of Gastroenterology-Research Hospital, IRCCS "S. de Bellis", Bari, Italy, ⁶ Department of Radiological Oncological and Pathological Sciences, University La Sapienza, Rome, Italy, ⁷ Department of Surgery Pietro Valdoni, Faculty of Medicine and Dentistry, Sapienza University of Rome, Rome, Italy, ⁸ Department of Experimental Medicine, University La Sapienza, Rome, Italy, ⁹ Center for Life Nano Science@Sapienza, Istituto Italiano di Tecnologia, Rome, Italy, ¹⁰ Pasteur Institute-Cenci Bolognetti Foundation, Rome, Italy

Extensive molecular characterization of human colorectal cancer (CRC) via Next Generation Sequencing (NGS) indicated that genetic or epigenetic dysregulation of a relevant, but limited, number of molecular pathways typically occurs in this tumor. The molecular picture of the disease is significantly complicated by the frequent occurrence of individually rare genetic aberrations, which expand tumor heterogeneity. Inter- and intratumor molecular heterogeneity is very likely responsible for the remarkable individual variability in the response to conventional and target-driven first-line therapies, in metastatic CRC (mCRC) patients, whose median overall survival remains unsatisfactory. Implementation of an extensive molecular characterization of mCRC in the clinical routine does not yet appear feasible on a large scale, while multigene panel sequencing of most commonly mutated oncogene/oncosuppressor hotspots is more easily achievable. Here, we report that clinical multigene panel sequencing performed for anti-EGFR therapy predictive purposes in 639 formalin-fixed paraffin-embedded (FFPE) mCRC specimens revealed previously unknown pairwise mutation associations and a high proportion of cases carrying actionable gene mutations. Most importantly, a simple principal component analysis directed the delineation of a new molecular stratification of mCRC patients in eight groups characterized by non-random, specific mutational association patterns (MAPs), aggregating samples with similar biology. These data were validated on a The Cancer Genome Atlas (TCGA) CRC dataset. The proposed stratification may provide great opportunities to direct more informed therapeutic decisions in the majority of mCRC cases.

Keywords: mCRC, NGS, molecular stratification, mutation, genes

INTRODUCTION

Colorectal carcinoma (CRC) is one of the most commonly diagnosed cancers worldwide (1, 2). A large proportion of patients develop distant metastasis, which contributes to the high mortality reported for this tumor. With the current standard approaches, the 5-year survival rate for metastatic CRC (mCRC) is about 13% (1–3). These oxaliplatin or irinotecan-based chemotherapy regimens allow a median overall survival (OS) of about 18–20 months (4, 5). Survival rates can be significantly improved by a “triplet” approach consisting of 5-FU, oxaliplatin, and irinotecan chemotherapy (6) and/or by the addition of targeted drugs, such as monoclonal antibodies directed against angiogenesis or EGFR pathway (7). Nonetheless, median OS for mCRC rarely exceeds 30–36 months (8–10). Unfortunately, individual responses to these therapeutic approaches may be dramatically different from patient to patient reflecting the broad inter- and intratumor molecular heterogeneity.

Historically, CRC represented the first model for multistep cancer evolution in which discrete and sequential genetic modifications in specific oncogenes and tumor-suppressor genes occur throughout cancer progression (11, 12). Next Generation Sequencing (NGS) provided significant advances in understanding the molecular basis of CRC (13–15) and indicated that genetic or epigenetic dysregulation of a relevant, but limited, number of molecular pathways typically occurs in human CRC (13, 15, 16). This molecular picture is complicated by the frequent occurrence of individually rare genetic aberrations, which further expand tumor heterogeneity (13–15).

Reflecting the different biology of CRCs, Guinney et al. recently proposed a molecular classification in four consensus molecular subtypes (CMS): CMS1-MSI immune, CMS2-canonical, CMS3-metabolic, and CMS4-mesenchymal (13). Although this might have implications for prognostication and therapy decisions, its immediate transfer to routine diagnostic/clinical settings is seriously challenging in terms of methodology, turnaround time, costs, and mindset. In fact, despite NGS and other omic approaches may disclose a huge amount of molecular details, still very few of them have yet acquired clinical relevance. In example, the use of anti-EGFR therapy is essentially dictated by the RAS (KRAS+NRAS) wild type status, in the clinical routine (17, 18), which however is largely insufficient for the positive selection of responsive patients (19, 20). Treatment with anti-VEGF antibodies is not driven by specific selection criteria due to lack of validated molecular biomarkers (21, 22). Other targeted approaches (i.e., BRAF or PI3K inhibitors used as single agents) failed due to resistance mechanisms (23). These evidences support the need for a paradigm shift in personalized medicine, as suggested by Dienstmann et al. (24): from a one-gene one-drug approach, to a multi-gene multi-drug perspective.

The use of multigene panel sequencing has been recently validated for clinical applications. In example, we introduced a 22 multigene panel sequencing, which includes the clinically relevant RAS and BRAF hotspots, as a routine for the predictive selection of mCRC patients to be subjected to anti-EGFR therapy (25–32). This implementation allowed us to accumulate a large

dataset to ask the question of whether application of multigene panel sequencing to the standard diagnostics of mCRC could provide clinically useful information, with no extra-costs in terms of turnaround time and money.

On the basis of results obtained on 639 formalin-fixed and paraffin-embedded (FFPE) tumor samples, here we report that clinical genomic profiling with a multigene panel identifies distinct molecular association patterns (MAPs) and provides great opportunities to unveil co-occurrence of actionable gene mutations to direct more appropriate therapeutic decisions for the majority of mCRC patients.

PATIENTS AND METHODS

Specimen Collection

A total of 779 FFPE tumor samples from mCRC patients were collected from Policlinico Umberto I (Rome, Italy) and from the Department of Public Health, University Federico II, Naples, Italy. The large majority of samples (696/779) were from the primary site, while few (83/779) were from metastatic sites. All samples reached the molecular pathology labs with a medical prescription for determination of RAS/BRAF mutation status for predictive purposes. As such, only scattered clinical-pathological information was available for the two series. For this retrospective observational study all investigations were approved by the Ethics Committee of the University La Sapienza (Prot.: 88/18; RIF.CE:4903, 31-01-2018). All information regarding human material included in the study was managed using anonymous numerical codes, and all samples were handled in compliance with the principles outlined in the declaration of Helsinki. For samples collected at the Department of Public Health, University Federico II, we obtained written informed consent from all patients, in accordance with the general authorization to process personal data for scientific research purposes from “The Italian Data Protection Authority (<http://www.garanteprivacy.it/web/guest/home/docweb/-/docwebdisplay/export/2485392>).

DNA Extraction

Tissue samples with a content of tumor-vs.-non-tumor cells below 20% (evaluated at the observation of Hematoxylin and Eosin stained slides) were excluded from the analysis (33). The tumor area was macroscopically dissected to concentrate tumor tissue. Xylene was added once and ethanol was added twice to remove all paraffin from the tissue sample (34). DNA was extracted using QIAamp DNA FFPE Tissue kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer’s instructions. Eluted DNA was quantified with Qubit 2.0 Fluorometer (Thermo Fisher Scientific, Van Allen Way, Carlsbad, CA 92008, USA) using Qubit™ dsDNA HS Assay Kit (Thermo-Fisher Scientific, Eugene, Oregon 96492, USA).

IT-PGM Sequencing and Variant Calling

IT-PGM sequencing was achieved as described (25, 27, 35). Approximately, 10 ng of DNA samples was required to construct barcoded and adaptor-ligated libraries using the Ion AmpliSeq Library kit 2.0 (Thermo Fisher Scientific, Van Allen Way,

Carlsbad, CA 92008 USA) and Ion Xpress Barcode Adapter 1-16 Kit (Thermo Fisher Scientific, Van Allen Way, Carlsbad, CA 92008 USA). The samples were analyzed using Ion AmpliSeq Colon and Lung Cancer Research Panel V2 (CLV2, Thermo Fisher Scientific, Guilford, CT 06437, USA) containing a single primer pool to amplify hotspots and targeted regions of 22 cancer genes frequently mutated in CRCs and NSCLCs (29). Templated spheres were prepared using 100 pM of each library using the Ion One Touch 2.0 machine (Thermo Fisher Scientific, Van Allen Way, Carlsbad, CA 92008 USA). Template-positive spheres were loaded into Ion chip 314 or Ion chip 316 and sequenced by IT-PGM machine (Thermo Fisher Scientific, Van Allen Way, Carlsbad, CA 92008 USA). Sequencing data were analyzed with the Ion Torrent Suite (Thermo Fisher Scientific, <http://github.com/iontorrent/TS>). Variants with a quality <30 were filtered out.

For the purpose of the study, we generated a mutational data set including only samples carrying mutations of established clinical relevance for KRAS (mutations at codon 12, 13, 59, 61, 117, and 146), BRAF (V600E) and PIK3CA (mutations in exon 10 and 21). For TP53, we included in the study samples carrying mutations with defined pathogenic significance according to ClinVar and/or well-established hotspot mutations. We excluded from the study 140 samples carrying variants of unknown clinical significance (VUS) in these genes. For all other genes, we listed all genetic alterations described as pathogenic, likely-pathogenic or predicted deleterious by *in silico* analysis, while benign polymorphisms were not considered.

When appropriate, PolyPhen-2 (Polymorphism Phenotyping v2; <http://genetics.bwh.harvard.edu/pph2/>), PROVEAN/SIFT (Sort Intolerant From Tolerant Substitutions) http://provean.jcvi.org/protein_batch_submit.php?species=human) computational tools were used to predict the possible impact of the detected alterations on the structure and function of the protein (18, 19).

The reference sequence used are: KRAS NM_033360.3, TP53 NM_000546.5, PIK3CA NM_006218.3, BRAF NM_004333.4, NRAS NM_002524.4, FBXW7 NM_033632.3, SMAD4 NM_005359.5, PTEN NM_000314.6, MET NM_001127500.2, STK11 NM_000455.4, EGFR NM_005228.4, CTNNB1 NM_001904.3, AKT1 NM_001014431.1, ERBB2 NM_004448.3, ERBB4 NM_005235.2, FGFR1, NM_001174063.2, ALK NM_004304.4, MAP2K1 NM_002755.3, NOTCH1 NM_017617.4, DDR2 NM_001014796.3, FGFR3 NM_000142.4, FGFR2 NM_000141.4.

MSI Analysis

Determination of MSI status was investigated on 162 patients (72 of the 639 cases representing the main bulk of the study plus 90 additional cases collected at a later stage and analyzed separately). It was carried out by analysis of BAT25, BAT26, NR21, NR22, and NR24 mononucleotide repeats as previously described (36). Briefly, one PCR primer of each pair was labeled with 1 with either FAM, HEX, or NED fluorescent markers. PCR amplification was performed under the following conditions: denaturation at 94°C for 5 min, 35 cycles of denaturation at 94°C for 30 s, annealing at 55°C for 30 s, and extension at 72°C for 30 s. This was followed by an extension step at 72°C for 7 min.

PCR products were run on ABI PRISM 3130xl Genetic Analyzer (16 capillary DNA sequencer, Applied Biosystem). Gene Mapper software 5 (version 5.0, Applied Biosystems, Van Allen Way, Carlsbad, CA 92008, USA) was used to calculate the size of each fluorescent PCR product.

Statistical Analysis

The mutational data set was organized in a matrix composed by 20 columns and 639 rows where each row corresponds to a different sample and each column corresponds to one of 22 different genes whose mutational pattern was characterized. We performed a Principal Component Analysis (PCA) on this mutational dataset in order to classify mutational patterns based on their similarity. Each matrix element M_{ij} (where i is a generic sample and j is a generic gene) can assume the value 0 or 1 if the patient i has no mutation in the gene j or the mutation is present, respectively (37). Each principal component is a linear combination of optimally-weighted original variables, and so it is often possible to ascribe meaning to what the components represent. The statistical analysis was carried out with SPSS statistics or standard R software, version 2.13.1 (<http://www.r-project.org>).

Statistical analyses on gender, tumor type, tumor location, and MSI-H phenotype were performed on all cases for which appropriate information was available, using both the 639 and the 90 series.

The Pearson's Chi-square test and Fisher's exact test of association was used to determine the relationship between two categories which consist in coexistence of two mutations (pairwise association analysis). A $p < 0.05$ was considered statistically significant.

TCGA Network Data set

We downloaded gene somatic mutations for 625 patients from the TCGA data portal (<https://portal.gdc.cancer.gov/>) accessed December 2018 (38, 39). We cleared this dataset from samples carrying VUS, as we did for our dataset (see above). The resulting data set contained 412 patients with their mutational data of the 22 genes included in the CLV2 panel.

We employed the R package TCGAbiolinks (40) to retrieve patient's Microsatellite Instability (MSI) status from the legacy archive of GDC data portal (<https://portal.gdc.cancer.gov/>).

RESULTS

Mutation Profiling of mCRCs, Pairwise Associations, and Identification of Actionable Targets

Using a 22 gene panel NGS approach, we detected pathogenic mutations in at least one of the 22 targets in 523 out of 639 (81.8%) mCRC samples (Table S1). Mutation spectra and frequencies were in line with previous reports (14, 15, 31) (Figure 1A). Eleven genes displayed a mutation frequency >1.5% (mutation number >10), being TP53 and KRAS the most frequently mutated genes (48.5 and 39.4%, respectively) (Figure 1A). Mutations occurred less frequently (<1.5%) in the other 11 genes (CTNNB1, AKT1, ERBB2, ERBB4, FGFR1, ALK,




FIGURE 1 | Mutation frequencies and pairwise associations. **(A)** Mutation rates (and absolute numbers of the bars) in 639 metastatic colorectal cancers. **(B)** Correlation Plot describing pairwise association of the mutations occurring on the 11 genes with a mutation frequency > 1.5% (mutation number > 10). Statistical analysis is given **Table 1**. **p* < 0.05.

MAP2K1, *NOTCH1*, *DDR2*, *FGFR3*, and *FGFR2*), consistent with the “tail effect” associated with NGS profiling of tumor samples (15) (**Figure 1A**).

To investigate on mutation associations, we initially performed a pairwise association analysis for those genes with a mutation frequency > 1.5%. In agreement with previous

literature, *BRAF*, *KRAS*, *NRAS* mutations were mutually exclusive, while *PIK3CA* and *FBXW7* mutations frequently occurred in association with *KRAS* mutations. *BRAF* and *SMAD4* mutations were associated, while *TP53* and *KRAS* mutations were negatively associated (**Figure 1B**, **Table 1**). We also revealed previously unreported positive association between

TABLE 1 | Significant pairwise associations between most frequent gene mutations.

Gene ^a	Status	Wt (%)	Mut (%)	p ^b	References
KRAS (%)					
TP53	Mut	200 (51.7)	110 (43.7)	0.047	(44)
PIK3CA	Mut	38 (9.8)	61 (24.2)	<0.001	(43)
BRAF	Mut	50 (12.9)	1 (0.4)	<0.001	(43)
NRAS	Mut	30 (7.8)	1 (0.4)	<0.001	(43)
FBXW7	Mut	20 (5.2)	23 (9.1)	0.05	(31)
EGFR	Mut	3 (0.8)	8 (3.2)	0.03*	New
PIK3CA (%)					
FBXW7	Mut	31 (5.7)	12 (12.1)	0.02	(45)
BRAF (%)					
SMAD4	Mut	23 (3.9)	6 (11.8)	0.022*	(46)
PTEN	Mut	18 (3.1)	5 (9.8)	0.03*	New
EGFR (%)					
SMAD4	Mut	26 (4.1)	3 (27.3)	0.011*	New
TP53 (%)					
NRAS	Mut	9 (2.7)	22 (7.1)	0.01	New

^aThe genes with an overall mutational rate higher than 1.5% (number of mutations >10) were considered for statistical analysis. ^bChi-squared test.

*Fisher exact test.

EGFR mutations and *KRAS* and *SMAD4* mutations, while *BRAF* mutations were significantly associated with *PTEN* mutations (Figure 1B, Table 1, Table S2). At variance from *KRAS*, *NRAS* mutations were significantly associated with *TP53* mutations.

Overall, 374/639 (58.5%) patients carried actionable gene mutations, as defined by Chakravarty et al. (41), and 153 patients carried druggable alterations. Importantly, the vast majority of patients positive or negative for specific actionable mutations frequently carried additional relevant genetic alterations (Table 2), which in principle could contribute to an individual variability in patients' responsiveness to standard and target-driven therapies. In example, only 27 (4.2% of the entire series) of the 99 patients carrying *PIK3CA* mutations were *RAS/BRAF* WT and only 9 of these (1.4% of the entire series) harbored exclusively *PIK3CA* mutations. On the same line, 17/639 (2.7%) patients carried only *BRAF* mutations, while 34 *BRAF* mutant samples also carried additional mutations.

Identification of Mutational Association Patterns (MAPs)

Although pairwise associations might provide interesting insights into the molecular nature of CRC and represents a step forward in considering the molecular complexity of cancer for prognostic and predictive purposes, we reasoned that a more comprehensive use of the entire mutational profile of each sample could help defining a novel and more precise classification of CRC.

Thus, we subjected our large dataset to a principal component analysis (PCA) with the aim to detect those genes which better classify the different samples based on their overall mutational profile. This approach clearly indicated that two

TABLE 2 | Frequency of co-mutation in genes carrying actionable mutations.


	Status	No. of pts. (%)	No. of pts. (%) with additional mutations
<i>KRAS</i>	WT	387 (60.6)	270 (42.2)
	Mut	252 (39.4)	176 (27.5)
<i>NRAS</i>	WT	608 (95.2)	491 (76.8)
	Mut	31 (4.8)	26 (4.1)
<i>BRAF</i>	WT	588 (92.0)	471 (73.7)
	Mut	51 (8.0)	34 (5.3)
<i>PIK3CA</i>	WT	540 (84.5)	423 (66.2)
	Mut	99 (15.5)	89 (13.9)
<i>EGFR</i>	WT	629 (98.4)	512 (80.1)
	Mut	10 (1.6)	9 (1.4)
<i>MET</i>	WT	633 (99.1)	516 (80.7)
	Mut	6 (0.9)	6 (0.9)
<i>PTEN</i>	WT	618 (96.7)	501 (78.4)
	Mut	21 (3.3)	20 (3.1)
<i>AKT1</i>	WT	634 (99.2)	517 (80.9)
	Mut	5 (0.8)	4 (0.6)
<i>ERBB2</i>	WT	636 (99.5)	519 (81.2)
	Mut	3 (0.5)	3 (0.5)
<i>ALK</i>	WT	638 (99.8)	521 (81.5)
	Mut	1 (0.2)	1 (0.2)
<i>MAP2K1</i>	WT	638 (99.8)	521 (81.5)
	Mut	1 (0.2)	1 (0.2)

genes (*TP53* and *KRAS*) could sharply cluster our samples into four different subsets: *TP53*^{wt}/*KRAS*^{wt} samples, *TP53*^{mut}/*KRAS*^{wt} samples, *TP53*^{wt}/*KRAS*^{mut} samples, and *TP53*^{mut}/*KRAS*^{mut} samples (Figure 2). While mutations in other genes could also aggregate our samples into distinct subsets (see for example *PIK3CA* and *BRAF*, Figure 2), they never reached the sharp effectiveness of *TP53* and *KRAS* mutations.

Thus, in accordance to PCA results, we stratified the 639 CRC cases into four different mutation association patterns (MAPs) based on *TP53* and *KRAS* mutation status (Figure 3A). Depending on the presence/absence of mutations in genes other than *TP53* and *KRAS*, each MAP could be further divided in two subsets leading to delineation of a total of eight different MAPs (Figure 3A).

This stratification promptly revealed that 18.2% of the samples carried no mutations in any of the 22 gene of the panel (MAP4.2), while 29.4% harbored only one mutation in either *KRAS* or *TP53* (MAP2.2 and MAP3.2, respectively). An additional 11.6% of the patients only carried *KRAS* and *TP53* mutations with no other alterations (MAP1.2), which indicates that a large fraction of the mCRC cohort is characterized by a very low mutation rate, as detectable by our gene panel sequencing.

The distribution of mutations in genes other than *TP53* and *KRAS* also occurred non-randomly among the MAPs (Figures 3A,B) clearly defining distinct molecular profiles. Indeed, the Pearson's Chi-square test and Fisher's exact test showed statistical significance for almost all the comparisons between the MAPs (Table S3). In details, the eight MAPs are characterized as follows.



MAP1.1. This MAP, characterized by the $TP53^{mut}/KRAS^{mut}$ status, showed a high rate of *PIK3CA* mutations (52.8%), rare (2.8%) $BRAF^{V600E}$ mutations and no *NRAS* alterations. We also found a relevant number of *FBXW7* mutations (27.8%), and some *PTEN* (11.1%) and *SMAD4* mutations (8.3%), most often mutually exclusive with *PIK3CA* mutations.

MAP1.2. This MAP was characterized by the $TP53^{mut}/KRAS^{mut}$ status, and no additional mutations.

MAP2.1. This MAP, characterized by $TP53^{wt}/KRAS^{mut}$ status, showed the highest frequency of *PIK3CA* mutations (62.7%). Intriguingly, 3 out of 5 E17K *AKT1* mutations occurred in *PIK3CA* WT samples in this MAP, concurring to the activation of the same pathway.

A fair amount of *FBXW7* mutations (19.4%) and a few *SMAD4* mutations (9.0%), but no *BRAF* and rare *NRAS* mutations (1.5%) occurred in MAP2.1. Coherent with the previously mentioned *KRAS* pairwise association, the rare *EGFR* mutations clustered in MAP1.1 and MAP2.1.

MAP2.2. This MAP was characterized by the $TP53^{wt}/KRAS^{mut}$ status, and no additional mutations.

MAP3.1. This MAP, characterized by $TP53^{mut}/KRAS^{wt}$ status, had a high frequency of *BRAF* (20.5%), combined with

the highest frequency of *NRAS* (in a mutually exclusive way) and *SMAD4* mutations (25.0 and 18.2%, respectively). This group also showed *PIK3CA* mutations in 23.9% of the samples, at least partially non-overlapping with *BRAF*, *NRAS*, and *SMAD4* mutations, and the lowest frequency of *FBXW7* mutations (5.7%).


MAP3.2. This MAP was characterized by the $TP53^{mut}/KRAS^{wt}$ status, and no additional mutations.

MAP4.1. In this MAP, characterized by $TP53^{wt}/KRAS^{wt}$ status, we found the highest frequency of *BRAF* mutations (45.1%) and the lowest amount of *SMAD4* mutations (5.6%). It also showed mutations in *PIK3CA*, *NRAS*, and *FBXW7*, respectively, in 23.9, 11.3, and 21.1% of the samples.

MAP4.2. This MAP was characterized by absence of mutations.

Importantly, the analysis of microsatellite instability (MSI) on a test group of 162 samples revealed that 9 tumors were MSI-H. 6 out of 9 MSI-H samples clustered into MAP4.1, 2 in MAP3.1 and 1 in MAP4.2 (Table 3), which suggests that the proposed mutational stratification is able to aggregate samples with similar biology.

Mutation distribution of other genes did not vary significantly among MAPs and/or was too low to support major conclusions.



Identification of MAPs on the TCGA Dataset

To validate MAPs in an external dataset, we accessed the TCGA public mutational data for CRC patients. After appropriate curation of the dataset in order to select all pathogenic mutations potentially identifiable by our multigene panel sequencing approach, we had 412 samples available for MAP stratification. Of interest, the TCGA dataset included all CRC stages, and only a minority of the cases were mCRC (**Figure S1A**), as already noted by others (14, 42).

The mutation frequencies on the 22 genes included in the CLV2 panel were largely similar between TCGA dataset and our mCRC cohort (**Figure S1B**). All different MAPs exist with rather similar rates, in TCGA dataset and our series, with MAP 4.1

and MAP4.2 representing sharp exceptions. Indeed, MAP 4.1 accounts for 11.1% of our series of mCRC samples, compared to 18.0% of the TCGA dataset, while MAP4.2 accounts for 18.2% in our series and 5.3% of the TCGA dataset. At variance from our cohort, TCGA dataset included 14% of MSI-H samples, which is consistent with its stage 1-to-stage 4 composition (14). The majority of these cases clustered in MAP4.1, possibly providing an explanation for the different MAP4 rates between the two datasets.

PIK3CA, BRAF, and NRAS mutation rates in the different MAPs display similar trends in our metastatic cohort and in the TCGA dataset (**Figures S2A,B**). We observed less consistency for the mutation rates of the less frequently mutated FBXW7, SMAD, and PTEN genes.

TABLE 3 | Associations between selected features and MAPs.

		No.	%	MAPs								p
				1.1	1.2	2.1	2.2	3.1	3.2	4.1	4.2	
Gender	M	346	60.1	29 (8.40%)	44 (12.7%)	35 (10.1%)	37 (10.7%)	44 (12.7%)	64 (18.5%)	34 (9.8%)	59 (17.1%)	0.301
	F	230	39.9	15 (6.5%)	37 (16.1%)	28 (12.2%)	26 (11.3%)	41 (17.8%)	33 (14.3%)	22 (9.6%)	28 (12.2%)	
Site	Rectum	89	15.5	9 (10.1%)	14 (15.7%)	17 (19.1%)	5 (5.6%)	9 (10.1%)	13 (14.6%)	6 (6.7%)	16 (18.0%)	0.058
	Colon	486	84.5	35 (7.2%)	67 (13.8%)	46 (9.5%)	58 (11.9%)	76 (15.6%)	84 (17.3)	50 (10.3%)	70 (14.4%)	
Side	Right	183	55.3	12 (6.6%)	31 (16.9%)	23 (12.6%)	18 (9.8%)	36 (19.7%)	15 (8.2%)	34 (18.6%)	14 (7.7%)	<0.0001
	Left	148	44.7	12 (8.10%)	17 (11.5%)	15 (10.1%)	19 (12.8%)	24 (16.2%)	36 (24.3%)	3 (2.0%)	22 (14.9%)	
MSI	absent	153	94.4	19 (12.4%)	31 (20.3%)	20 (13.1%)	14 (9.2%)	25 (16.3%)	24 (15.7%)	3 (2.0%)	17 (11.1%)	*<0.0001
	present	9	5.6	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)	0 (0.0%)	6 (66.7%)	1 (11.1%)	

*Fisher's exact test. Bold: statistically significant.

Correlation Between Clinical-Pathological Features and MAPs

Next, we examined how MAP stratification correlated with gender and tumor site, the only variables we had available for a reasonable number of patients (Table 3). MAP stratification did not significantly correlate with gender. Concerning tumor site, differences in MAP distribution between colon and rectal localization were close to statistical significance, with a trend for MAP2.1 to be more represented and for MAP2.2 and MAP3.1 to be less represented in rectum compared to colon cancer (Table 3). Moreover, while MAP1 and MAP2 have similar frequencies among right-side and left-side CRC, MAP3.2 and MAP4.2 (accounting for by samples with no mutations or TP53 mutations only) were overrepresented in left-side CRC, and MAP4.1 was overrepresented in right-side CRC. Of relevance, the association of MAP 4.1 with right side remains significant even by omitting MSI-H cases (not shown).

DISCUSSION


The response of mCRC to current therapeutic approaches is highly variable, reflecting the elevated heterogeneity of the disease (7). This, together with an increasing availability of targeted therapeutic approaches, stresses the need for more comprehensive molecular characterization of each tumor sample, in order to push forward the real achievement of personalized interventions. Despite it is clear that an extended molecular characterization of CRC patients may significantly impact on their clinical management (27–30), very little has entered the clinical routine, yet.

Here, we report that a clinical genomic profiling via multigene panel sequencing allowed identification of pairwise mutation associations and eight distinct MAPs, providing great opportunities to direct more informed therapeutic decisions, in the majority of mCRC cases.

Our data confirm previously reported pairwise gene mutation associations (31, 43–46) and unveil for the first time EGFR/KRAS, EGFR/SMAD4, BRAF/PTEN, and NRAS/TP53 positive associations. The biological or clinical meaning of these associations is difficult to trace, at the moment. In example, while

mutations in the EGFR tyrosine-kinase domain are mutually exclusive with KRAS mutations and are positive predictive biomarkers for the efficacy of tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC) (34, 47), these mutations are rare and scarcely relevant in predicting responses to antibody-based anti-EGFR therapy, in mCRC (48). 8/11 EGFR mutation occurring in our mCRC cohort coexist with KRAS mutations. On one side, this may imply that coexisting EGFR and KRAS activating mutation might provide additional advantages to tumor progression in mCRC. This is also supported by the frequent co-occurrence of KRAS and PIK3CA, leading to the constitutive activation of two different pathways downstream of the EGFR. Alternatively, EGFR and KRAS mutations could also exist in different subclonal mCRC populations in the same tumor, as a result of tumor heterogeneity, driving the activation of the same pathway. Addressing the details of tumor heterogeneity and clonality, by tumor multisampling and/or single cell sequencing, will be required to address these issues.

Clinical multigene panel sequencing may easily lead to the identification of actionable and targetable gene mutations (27–31). More importantly, it provides awareness that specific actionable/targetable mutations most frequently co-occur with additional relevant genetic alterations, which in principle could contribute to an individual variability in patients' responsiveness to standard and target-driven therapies. Overlooking this molecular complexity may account for treatment failures, when approved or innovative targeted approaches are used. The scant success of PI3K inhibitors in mCRC may be at least in part due to PIK3CA mutations co-occurring with RAS/BRAF mutations (more than 70% of the PIK3CA^{mut} patients in our cohort) (49). It cannot be excluded that other gene mutations (occurring in an additional 18% of the PIK3CA^{mut} patients in our cohort) may also provide primary resistance to PI3K inhibitors. Only 1.4% of our entire cohort carried exclusively PIK3CA mutations, possibly underscoring a subset of patients best suited for treatment with PI3K inhibitors. On the same line, 2.7% (17/639) of the patients carried only BRAF mutation, possibly representing the best subset for a target treatment with BRAF^{V600E} inhibitors alone, or in combination with anti-EGFR (50, 51). Most patients carrying BRAF^{V600E} also carried additional mutations, at least some of



which might be expected to be involved in primary resistance to anti-BRAF therapies, providing contraindication to single target approaches. In line with this, a phase III 3-arm trial is currently exploring the effectiveness of a triplet therapy with the BRAF inhibitor plus MEK inhibitor associated with the anti EGFR antibody CETUXIMAB in *BRAF*^{V600E} mCRC, in the second or third-line setting (BEACON CRC NCT02928224) (23).

Most importantly, we believe that the greatest added value of clinical multigene panel sequencing may come from a more comprehensive use of the entire mutational profile of each patient to implement a more precise molecular stratification of mCRC. In this observational study, we developed a new stratification system into eight distinct MAPs characterized by non-random, specific mutational combinations. We validated these findings via TCGA data analysis, although few interesting differences emerged. In particular, the different rate of MSI-H cases and the different size of MAP4.1 may be due to the different stage composition between our cohort and TCGA dataset. Whether this is also relevant for the different size of MAP4.2 and the different distribution of some less frequently mutated genes remains to be determined.

Although we are aware that the lack of clinical data only allows for a speculative proposition, we believe that our comprehensive molecular stratification may provide the base for informed therapeutic decisions, for the majority of mCRC patients, as detailed below (Figure 4).

Firstly, about 50% of our cohort bears no mutations at all (MAP4.2) or just one mutation (MAP2.2 and MAP3.2). An additional 11.6% of patients is characterized by mutations limited to *KRAS* and *TP53* (MAP1.2). Even considering the almost ubiquitous activation of the WNT pathway due to mutations in *APC*, β -catenin or *RNF43* genes (14), these data suggest that the majority of mCRC develop and progress with a low mutation load, which has significant implications for therapeutic

interventions. Of interest, the little representation of MAP4.2 in the mixed-stages TCGA dataset compared to our mCRC cohort seems to suggest a higher tendency to cancer progression and a negative prognostic value to having no detectable pathogenic mutations, in addition to being less responsive to common therapies (27). This interesting hypothesis also needs to be confirmed in independent series.

MAP1.1 patients (as well as MAP1.2, MAP2.1, and MAP2.2 patients) are not eligible for anti-EGFR therapy, due to *KRAS* mutations. More in general, therapies directed against single targets are likely to fail in this group of patients due to primary resistance, as a consequence of having ≥ 3 gene mutations. Appropriate multitarget combinations should instead be considered for this group, taking advantage of the druggable mutations detected in each patient. Inhibitors of immune-checkpoints are effective in MSS patients (52). The presence of ≥ 3 pathogenic mutations/tumor in MAP1.1 may suggest a higher mutation rate (compared to MAP 2.2/4.2), raising the possibility to test the efficacy of checkpoint inhibitors, in this subset.

Due to the occurrence of multiple mutations, target driven drug combinations also need to be considered for MAP2.1. However, in this subset we noticed the highest frequency of *PIK3CA* mutations (42/66), 5/66 *PTEN* mutations and 3 out of the 5 *AKT1* mutations, mutually exclusive with *PIK3CA* mutations. Thus, the highest frequency of constitutive activation of the PI3K-AKT1 pathway occurs in this *TP53* WT subset. It has been shown that p53 may limit *KRAS* dependent transformation (53), suggesting that p53 inactivation may be required for *KRAS*-dependent cancer development. Nonetheless, *KRAS* and *TP53* mutations are not positively associated in mCRC (31, 44), at variance with *NRAS* mutations. Of interest, PI3K-AKT axis impinges on *MDM2*, promoting an increased E3-ubiquitin ligase activity, ultimately leading to p53 functional inactivation via

increased degradation (54). Therefore, activation of the PI3K-AKT pathway provides a functional mean to inactivate p53, in KRAS mutant samples. Consistent with this, Singh et colleagues found mutually exclusive occurrence of *TP53* mutations and *PIK3CA* amplification in squamous cell carcinomas (55). This support the possibility that TP53 reactivation approaches, which are being tested elsewhere (56), could also find application in MAP2.1 mCRC (Figure 4).

Beside standard treatment including anti-VEGF, additional intervention is hard to prospect for MAP1.2 patients, since they lack targetable gene mutations, with the possible exception of MEK inhibitors. Mutant TP53 reactivation approaches are yet to come at the clinical level, but they will find potential application also in this mCRC subset. The role of immunotherapy in this subset and in MAP2.2 patients seems counterintuitive, due to the low mutation rate.

Targeting EGFR as a single strategy will probably be ineffective for most patients of MAP3.1 due to the frequent occurrence of *PIK3CA*, *NRAS*, *BRAF*, or *SMAD4* mutations, all of which have been related to primary resistance to this approach (17, 43, 57, 58). Therefore, combination treatments should also be carefully planned in this subset. Importantly, few MSI-H patients fall in this group creating opportunities for immune system reactivation therapies.

In sharp contrast, MAP3.2 and MAP4.2 patients, largely coincident with the known “quadruple negative” mCRC subset (24, 59), are probably the most eligible to chemotherapy plus anti-EGFR therapies, since they lack known predictable resistance mechanisms. Of interest, these subsets are prevalent in the left colon, consistent with the observation that TP53 mutations and alternative mechanisms of activation of receptor tyrosine kinase pathways characterize tumors developing in the distal colon (14). These data also fit with the recently reported increased chance of response to anti-EGFR treatment in left colon mCRC (60, 61).

mCRCs of the MAP4.1 subset are predominantly localized to the right colon, where tumors appear to be less responsive to conventional therapies (60, 62). In this subset we detected the highest percentage of *BRAF*^{V600E} mutant patients, suggesting multiple targeting of *BRAF*^{V600E} and EGFR, perhaps also in combination with MEK inhibitors (50, 63). Anti-EGFR therapy alone should be possibly avoided, due to the frequent occurrence of primary resistance mutations in *PIK3CA*, *NRAS*, *BRAF*, or *FBXW7* (17, 43, 57, 58). TP53 reactivation may also seem reasonable, in cases with *NRAS* and *PIK3CA* mutations, similar to MAP2.1 patients. Finally, MAP4.1 also includes the majority of MSI-H mCRC patients, which are most likely to benefit from immune checkpoint inhibitors (52).

Although we are aware that our clinical genomic profiling does not take into account copy number variations and genomic rearrangements that may lead to derangement of specific oncogenic/oncosuppressive pathways, these rarely occur in mCRC (14). It remains that the major limitation of our study is that we had no access to homogeneously collected clinical data, which clearly prevented us from reaching significant clinical conclusion. In example, we cannot infer

whether any of the MAPs indicates a better response to anti-VEGF therapy, which is still orphan of biomarkers. Nonetheless, we believe that the simple and cost-effective molecular stratification of mCRC compatible with clinical settings described in this observational study will encourage us and others to design prospective studies to specifically address its effective value for more personalized therapeutic intervention of mCRC patients.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are publicly available. This data can be found here: NCBI SRA (<https://www.ncbi.nlm.nih.gov/bioproject/PRJNA614492/>).

ETHICS STATEMENT

For this retrospective observational studies all investigations were approved by the Ethics Committee of the University La Sapienza (Prot.: 88/18; RIF.CE:4903, 31-01-2018). All information regarding human material included in the study was managed using anonymous numerical codes, and all samples were handled in compliance with the principles outlined in the declaration of Helsinki. For samples collected at the Department of Public Health, University Federico II, we obtained written informed consent from all patients, in accordance with the general authorization to process personal data for scientific research purposes from The Italian Data Protection Authority (<http://www.garanteprivacy.it/web/guest/home/docweb/-/docwebdisplay/export/2485392>).

AUTHOR CONTRIBUTIONS

FB performed NGS and statistical analyses, interpreted the results, and drafted the manuscript. CC recruited samples, collected clinical-pathologic data, and interpreted the results. UM, PPI, and FP recruited samples, performed NGS, and collected sequencing data. DR and EM performed statistical/bioinformatics analyses and interpreted the results. MY and CL performed NGS. PPa, PS, and CB performed statistical analyses. SM, VM, AC, AN, AG, MP, SD, FF, PI, SC, GC, and GT recruited samples and collected clinical-pathologic data. GG conceived, designed, coordinated the study, and drafted the manuscript. All authors reviewed, edited, and approved the manuscript for publication.

FUNDING

This work was supported by Italian Ministry of Education, Universities and Research-Dipartimenti di Eccellenza-L. 232/2016; AIRC grant (IG17734), Italian Ministry of University and Research, PRIN projects, Istituto Pasteur-Fondazione Cenci Bolognetti and Ricerca Scientifica di Ateneo La Sapienza, to GG. AIRC grant (IG17575) and Istituto Pasteur Fondazione Cenci Bolognetti to GC.

ACKNOWLEDGMENTS

FB was supported by Fondazione Umberto Veronesi; FF is a recipient of a fellowship of the Ph.D. Programme in Tecnologie Biomediche in Medicina Clinica, University La Sapienza.

REFERENCES

- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA Cancer J Clin.* (2019) 69:7–34. doi: 10.3322/caac.21551
- Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal cancer statistics, 2017. *CA Cancer J Clin.* (2017) 67:177–93. doi: 10.3322/caac.21395
- van Cutsem E, Cervantes A, Nordlinger B, Arnold D, ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* (2014) 25(Suppl. 3):iii1–9. doi: 10.1093/annonc/mdu260
- Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. *J Clin Oncol.* (2005) 23:4866–75. doi: 10.1200/JCO.2005.07.113
- Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. *J Clin Oncol.* (2004) 22:229–37. doi: 10.1200/JCO.2004.05.113
- Golfinopoulos V, Salanti G, Pavlidis N, Ioannidis JPA. Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. *Lancet Oncol.* (2007) 8:898–911. doi: 10.1016/S1470-2045(07)70281-4
- Cremolini C, Schirripa M, Antoniotti C, Moretto R, Salvatore L, Masi G, et al. First-line chemotherapy for mCRC—a review and evidence-based algorithm. *Nat Rev Clin Oncol.* (2015) 12:607–19. doi: 10.1038/nrclinonc.2015.129
- Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. *J Clin Oncol.* (2009) 27:663–71. doi: 10.1200/JCO.2008.20.8397
- Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figuer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. *J Clin Oncol.* (2008) 26:2013–9. doi: 10.1200/JCO.2007.1.4.9930
- Van Cutsem E, Köhne C-H, Hitre E, Zaluski J, Chang Chien C-R, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *N Engl J Med.* (2009) 360:1408–17. doi: 10.1056/NEJMoa0805019
- Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. *Cell.* (1990) 61:759–67. doi: 10.1016/0092-8674(90)90186-I
- Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. *Science.* (2013) 339:1546–58. doi: 10.1126/science.1235122
- Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. *Nat Med.* (2015) 21:1350–6. doi: 10.1038/nm.3967
- Yaeger R, Chatila WK, Lipsyc MD, Hechtman JF, Cercek A, Sanchez-Vega F, et al. Clinical sequencing defines the genomic landscape of metastatic colorectal cancer. *Cancer Cell.* (2018) 33:125–36.e3. doi: 10.1016/j.ccell.2017.12.004
- Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. *Nature.* (2012) 487:330–7. doi: 10.1038/nature11252
- Capece D, Verzella D, Tessitore A, Alesse E, Capalbo C, Zazzeroni F. Cancer secretome and inflammation: the bright and the dark sides of NF- κ B. *Semin Cell Dev Biol.* (2018) 78:51–61. doi: 10.1016/j.semcdb.2017.08.004
- Douillard J-Y, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. *N Engl J Med.* (2013) 369:1023–34. doi: 10.1056/NEJMoa1305275
- van Cutsem E, Lenz H-J, Köhne C-H, Heinemann V, Tejpar S, Melezínek I, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. *J Clin Oncol.* (2015) 33:692–700. doi: 10.1200/JCO.2014.59.4812
- Allegra CJ, Rumble RB, Hamilton SR, Mangu PB, Roach N, Hantel A, et al. Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-Epidermal growth factor receptor monoclonal antibody therapy: American Society of clinical oncology provisional clinical opinion update (2015). *J Clin Oncol.* (2016) 34:179–85. doi: 10.1200/JCO.2015.63.9674
- Battaglin F, Puccini A, Ahcene Djallah S, Lenz H-J. The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer. *Cancer Manag Res.* (2019) 11:5911–24. doi: 10.2147/CMAR.S186042
- Rodriguez-Pascual J, Cubillo A. Dynamic biomarkers of response to antiangiogenic therapies in colorectal cancer: a review. *Curr Pharmacogen Person Med.* (2017) 15:81–5. doi: 10.2174/1875692115666170815161754
- Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. *Lancet Oncol.* (2010) 11:1172–83. doi: 10.1016/S1470-2045(10)70232-1
- Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Maru D, et al. Phase II pilot study of Vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. *J Clin Oncol.* (2015) 33:4032–8. doi: 10.1200/JCO.2015.63.2497
- Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. *Nat Rev Cancer.* (2017) 17:79–92. doi: 10.1038/nrc.2016.126
- Belardinilli F, Capalbo C, Buffone A, Petroni M, Colicchia V, Ferraro S, et al. Validation of the Ion Torrent PGM sequencing for the prospective routine molecular diagnostic of colorectal cancer. *Clin Biochem.* (2015) 48:908–10. doi: 10.1016/j.clinbiochem.2015.04.003
- Malapelle U, Vigliar E, Sgariglia R, Bellevicine C, Colarossi L, Vitale D, et al. Ion torrent next-generation sequencing for routine identification of clinically relevant mutations in colorectal cancer patients. *J Clin Pathol.* (2015) 68:64–8. doi: 10.1136/jclinpath-2014-202691
- Capalbo C, Belardinilli F, Raimondo D, Milanetti E, Malapelle U, Pisapia P, et al. A simplified genomic profiling approach predicts outcome in metastatic colorectal cancer. *Cancers.* (2019) 11:147. doi: 10.3390/cancers11020147
- Raimondi C, Nicolazzo C, Belardinilli F, Loreni F, Gradilone A, Mahdavian Y, et al. Transient disappearance of RAS mutant clones in plasma: a counterintuitive clinical use of EGFR inhibitors in RAS mutant metastatic colorectal cancer. *Cancers.* (2019) 11:42. doi: 10.3390/cancers11010042
- Gao XH, Yu GY, Hong YG, Lian W, Chouhan H, Xu Y, et al. Clinical significance of multiple gene detection with a 22-gene panel in formalin-fixed paraffin-embedded specimens of 207 colorectal cancer patients. *Int J Clin Oncol.* (2019) 24:141–52. doi: 10.1007/s10147-018-1377-1
- de Nicola F, Goeman F, Pallocca M, Sperati F, Pizzuti L, Melucci E, et al. Deep sequencing and pathway-focused analysis revealed multigene oncodriver signatures predicting survival outcomes in advanced colorectal cancer. *Oncogenesis.* (2018) 7:55. doi: 10.1038/s41389-018-0066-2
- Malapelle U, Pisapia P, Sgariglia R, Vigliar E, Biglietto M, Carlomagno C, et al. Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases. *J Clin Pathol.* (2016) 69:767–71. doi: 10.1136/jclinpath-2015-203403
- Del Vecchio F, Mastroiaco V, Di Marco A, Compagnoni C, Capece D, Zazzeroni F, et al. Next-generation sequencing: recent applications

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fonc.2020.00560/full#supplementary-material>

- to the analysis of colorectal cancer. *J Transl Med.* (2017) 15:246. doi: 10.1186/s12967-017-1353-y
33. Li W, Qiu T, Guo L, Ying J. Major challenges related to tumor biological characteristics in accurate mutation detection of colorectal cancer by next-generation sequencing. *Cancer Lett.* (2017) 410:92–9. doi: 10.1016/j.canlet.2017.09.014
 34. Belardinilli F, Gradilone A, Gelibter A, Zani M, Occhipinti M, Ferraro S, et al. Coexistence of three EGFR mutations in an NSCLC patient: a brief report. *Int J Biol Markers.* (2018) 33:1724600818782200. doi: 10.1177/1724600818782200
 35. Nicolussi A, Belardinilli F, Mahdavian Y, Colicchia V, D'Inzeo S, Petroni M, et al. Next-generation sequencing of BRCA1 and BRCA2 genes for rapid detection of germline mutations in hereditary breast/ovarian cancer. *PeerJ.* (2019) 7:e6661. doi: 10.7717/peerj.6661
 36. Suraweera N, Duval A, Reparant M, Vaury C, Furlan D, Leroy K, et al. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. *Gastroenterology.* (2002) 123:1804–11. doi: 10.1053/gast.2002.37070
 37. Jolliffe IT. *Principal Component Analysis*. 2nd ed. New York, NY: Springer-Verlag (2002). Available online at: <https://www.springer.com/us/book/9780387954424> (accessed January 27, 2019).
 38. Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, Mills GB, Shaw KRM, Ozenberger BA, et al. The cancer genome atlas pan-Cancer analysis project. *Nat Genet.* (2013) 45:1113–20. doi: 10.1038/ng.2764
 39. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature.* (2008) 455:1061–8. doi: 10.1038/nature07385
 40. Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, et al. TCGAAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. *Nucleic Acids Res.* (2016) 44:e71. doi: 10.1093/nar/gkv1507
 41. Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, et al. OncoKB: a precision oncology knowledge base. *JCO Precis Oncol.* (2017) 2017. doi: 10.1200/PO.17.00011
 42. Smeets D, Miller IS, O'Connor DP, Das S, Moran B, Boeckx B, et al. Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. *Nat Commun.* (2018) 9:4112. doi: 10.1038/s41467-018-06567-6
 43. de Roock W, Claes B, Bernasconi D, de Schutter J, Biesmans B, Fountzilias G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. *Lancet Oncol.* (2010) 11:753–62.
 44. Domingo E, Ramamoorthy R, Oukrif D, Rosmarin D, Presz M, Wang H, et al. Use of multivariate analysis to suggest a new molecular classification of colorectal cancer. *J Pathol.* (2013) 229:441–8. doi: 10.1002/path.4139
 45. Korphaisarn K, Morris VK, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, et al. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. *Oncotarget.* (2017) 8:39268–79. doi: 10.18632/oncotarget.16848
 46. Mehrvarz Sarshkeh A, Advani S, Overman MJ, Manyam G, Kee BK, Fogelman DR, et al. Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. *PLoS ONE.* (2017) 12:e0173345. doi: 10.1371/journal.pone.0173345
 47. Chan BA, Hughes BGM. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. *Transl Lung Cancer Res.* (2015) 4:36–54. doi: 10.3978/j.issn.2218-6751.2014.05.01
 48. Heinemann V, Stintzing S, Kirchner T, Boeck S, Jung A. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. *Cancer Treat Rev.* (2009) 35:262–71. doi: 10.1016/j.ctrv.2008.11.005
 49. Alzahrani AS. PI3K/Akt/mTOR inhibitors in cancer: at the bench and bedside. *Semin Cancer Biol.* (2019) 59:125–32. doi: 10.1016/j.semcancer.2019.07.009
 50. Capalbo C, Marchetti P, Coppa A, Calogero A, Anastasi E, Buffone A, et al. Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: a case report. *Cancer Biol Ther.* (2014) 15:826–31. doi: 10.4161/cbt.28878
 51. Ursem C, Atreya CE, van Loon K. Emerging treatment options for BRAF-mutant colorectal cancer. *Gastrointest Cancer.* (2018) 8:13–23. doi: 10.2147/GICCT.S125940
 52. Cohen R, Pellat A, Boussion H, Svrcek M, Lopez-Trabada D, Trouilloud I, et al. Immunotherapy and metastatic colorectal cancers with microsatellite instability or mismatch repair deficiency. *Bull Cancer.* (2019) 106:137–42. doi: 10.1016/j.bulcan.2018.09.004
 53. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. *Cell.* (1997) 88:593–602. doi: 10.1016/S0092-8674(00)81902-9
 54. Moll UM, Petrenko O. The MDM2-p53 interaction. *Mol Cancer Res.* (2003) 1:1001–8.
 55. Singh B, Reddy PG, Goberdhan A, Walsh C, Dao S, Ngai I, et al. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. *Genes Dev.* (2002) 16:984–93. doi: 10.1101/gad.973602
 56. Blandino G, Di Agostino S. New therapeutic strategies to treat human cancers expressing mutant p53 proteins. *J Exp Clin Cancer Res.* (2018) 37:30. doi: 10.1186/s13046-018-0705-7
 57. Cremolini C, Pietrantonio F. How the lab is changing our view of colorectal cancer. *Tumori.* (2016) 102:541–7. doi: 10.5301/tj.5000551
 58. Lupini L, Bassi C, Mlcochova J, Musa G, Russo M, Vychytilova-Faltejskova P, et al. Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients. *BMC Cancer.* (2015) 15:808. doi: 10.1186/s12885-015-1752-5
 59. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. *J Clin Oncol.* (2010) 28:1254–61. doi: 10.1200/JCO.2009.24.6116
 60. Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. *JAMA Oncol.* (2017) 3:194–201. doi: 10.1001/jamaoncol.2016.3797
 61. Lee GH, Malietzis G, Askari A, Bernardo D, Al-Hassi HO, Clark SK. Is right-sided colon cancer different to left-sided colorectal cancer? - a systematic review. *Eur J Surg Oncol.* (2015) 41:300–8. doi: 10.1016/j.ejso.2014.11.001
 62. Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V. The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. *Eur J Cancer.* (2017) 70:87–98. doi: 10.1016/j.ejca.2016.10.007
 63. Corcoran RB, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, et al. Combined BRAF, EGFR, and MEK inhibition in patients with BRAFV600E-mutant colorectal cancer. *Cancer Discov.* (2018) 8:428–43. doi: 10.1158/2159-8290.CD-17-1226

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The reviewer VS declared a past co-authorship with the authors to the handling editor.

Copyright © 2020 Belardinilli, Capalbo, Malapelle, Pisapia, Raimondo, Milanetti, Yasaman, Liccardi, Paci, Sibilio, Pepe, Bonfiglio, Mezi, Magri, Coppa, Nicolussi, Gradilone, Petroni, Di Giulio, Fabretti, Infante, Coni, Canettieri, Troncone and Giannini. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.